MONOCARBOXYLATE TRANSPORTER 4 (MCT4) ANTISENSE OLIGONUCLEOTIDE (ASO) INHIBITORS FOR USE AS THERAPEUTICS IN THE TREATMENT OF CANCER

Provided herein are compositions, method and uses for modulating MCT4 activity or for the treatment of cancer. The compositions comprise antisense oligonucleotides (ASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of MCT4. The cancer may b...

Full description

Saved in:
Bibliographic Details
Main Authors WANG, Yuzhuo, COLLINS, Colin C, XUE, Hui, GLEAVE, Martin E, CHOI, Stephen Yiu Chuen, GOUT, Peter Wilhelm
Format Patent
LanguageEnglish
French
Published 07.06.2018
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
DERIVATIVES THEREOF
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
SUGARS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Provided herein are compositions, method and uses for modulating MCT4 activity or for the treatment of cancer. The compositions comprise antisense oligonucleotides (ASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of MCT4. The cancer may be selected from one or more of: prostate cancer; renal cell carcinoma; breast cancer; cervical cancer; liver cancer; bladder cancer; and small cell lung cancer pr. The prostate cancer may be castration-resistant prostate cancer (CRPC). L'invention concerne des compositions, des procédés et des utilisations permettant de moduler l'activité de MCT4 ou destinés au traitement du cancer. Les compositions comportent des oligonucléotides antisens (ASO) destinés à être administrés à une cellule cancéreuse, la cellule cancéreuse pouvant être caractérisée par une expression élevée de MCT4. Le cancer peut être sélectionné parmi un ou plusieurs des cancers suivants : le cancer de la prostate, l'hypernéphrome, le cancer du sein, le cancer du col de l'utérus, le cancer du foie, le cancer de la vessie; et le cancer du poumon à petites cellules. Le cancer de la prostate peut être un cancer de la prostate hormono-résistant (CRPC).
Bibliography:Application Number: WO2016CA00296